Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer

Potentially eligible patients include all patients with stage I to IV lung cancer. Patient cannot have started systemic treatments or radiation treatments prior to enrollment on the study. Informed consent will be obtained in writing prior to initiating the study using a consent form approved by the local IRB. Inclusion criteria * Histologically confirmed lung cancer, or clinically diagnosed lung cancer. * AJCC stage I to IV lung cancer requiring radiation therapy (3D conformal or stereotactic) or systemic therapy, with or without surgery. * Patients participating treatment trials including targeted therapy, experimental therapy or immunotherapy are also eligible. * Patients with a locoregional tumor recurrence following surgery will be eligible provided they meet other eligibility criteria. * Patients must be 18 years of age or older and able to lie flat to obtain the functional scans or have blood access for blood samples * Female patients with reproductive capability must be willing to use effective contraception. * Patients must be willing and able to be compliant with all procedures and visits required for this protocol (pre-treatment, during treatment, and optionally throughout follow-up period). * Patients must sign an informed consent form for study. * Patients must be willing and able to adhere to a special low-carb diet 24-48 hours prior to and fast 8-12 hours prior to every 18F-FDG PET scan Exclusion criteria * Pregnancy if the patient is receiving radiation therapy * Lactation if the patient is receiving radiation therapy * Patients with diabetes mellitus, with uncontrolled fasting blood glucose level (above 200 mg/dl) * Inability to lie flat for the duration of PET/CT and V/Q SPECT/CT (approximately 45 minutes for each study)